The Acute Myeloid Leukemia Channel is supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals.
The Myelodysplastic Syndromes Channel is supported with funding from Geron (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2025 | Decoding DDX41: clinical impact of germline and somatic mutations in high-risk myeloid neoplasms
Talha Badar, MD, Mayo Clinic, Rochester, MN, reviews outcomes in patients with high-risk myeloid neoplasms harboring DDX41 mutations. Dr Badar highlights that while these patients often have favorable survival, responses to venetoclax-based therapy vary, and co-occurring mutations may drive resistance. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
